FDA Issues Safety Alert on Avandia
The U.S. Food and Drug Administration (FDA) has become aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Avandia is manufactured by GlaxoSmithKline. Data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials provide contradictory evidence about the risks in patients treated with Avandia.
